Merck's $73/Share Bio-Techne Acquisition Confirmed; Executive Retention Bonuses Approved
TECH sits 63% above its 52-week low of $43.195 on elevated volume (3.3× avg).
Summary
Merck's acquisition of Bio-Techne for $73 per share in an all-cash deal is confirmed, following the definitive merger agreement announced on June 25th. This news also reveals Bio-Techne has approved cash retention bonuses for executives Kim Kelderman and Jim Hippel, a common practice to ensure continuity during a merger. While Baird raised its price target to $73, this merely reflects the already public acquisition price. The deal awaits shareholder and regulatory approvals.
At the time of this announcement, TECH was trading at $70.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $43.20 to $72.16. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.